FAQ
Q: Are "immunosuppression" and "resolution of inflammation" the same thing?
+
A: Not exactly the same. Resolution **Emphasizes that inflammation is
terminated in an orderly manner and returns to homeostasis; **Immunosuppression** Emphasis
effect: **Immune function is suppressed, which may lead to a decline in clearance capacity. In practice,
both may occur simultaneously. It is recommended to interpret the results by comparing the suppression
panel from this topic with pro-inflammatory background indicators.
Q: How can I quickly determine if "anti-inflammatory negative feedback (braking)" has
occurred?
+
A: The most commonly used quick combination isIL-10 + TGF-β1If these two show
a significant increase after the peak of pro-inflammatory activity, it typically suggests enhanced
negative feedback/regulation; if pro-inflammatory levels remain high simultaneously, it is more likely
to be a transitional state of "coexistence of inflammation and suppression."
Q: Does an increase in IL-10 necessarily indicate "improvement/recovery"?
+
A: Not necessarily. An increase in IL-10 only indicates enhanced regulatory
signaling, which could mean it is declining or that the effector response is being suppressed. It is
recommended to combine it withTNF-α/IL-6Or compare with the main inflammatory readings of your project
during the same period to avoid misinterpreting "suppression" as "recovery."
Q: If I want to determine whether "effector immunity is suppressed," why is IL-2 + IFN-γ
recommended?
+
A: Because IL-2 More inclined towards "amplification and sustained
response potential", IFN-γ More inclined towards "effect output." When you expect a stronger
response but these two "don't rise or don't sustain," you need to consider suppressing the background or
time window issues; the enhanced version adds **IL-10 (±TGF-β1) help determine if there is an
inhibitory environment.
Q: Does low IFN-γ mean no T-cell response?
+
A: It is not advisable to draw a direct conclusion. IFN-γ is highly
influenced by the model, time point, type of stimulation, and sample type. It is recommended to cover at
least the "early/mid/late" time windows and make a comprehensive judgment in combination with IL-2 or
other effect readouts relevant to your model.
Q: Why is IL-6 + CCL2 (MCP-1) recommended for chronic inhibitory microenvironments?
+
A: IL-6 often indicates a background of chronic inflammation, while CCL2
suggests signals for monocyte/myeloid recruitment. When further combined with IL-10 (±TGF-β1),
this enhanced profile better reflects a suppressive environment characterized by the coexistence of
"chronic inflammation + recruitment + suppression," making it suitable for stratifying conditions in the
tumor microenvironment or chronic inflammation.
Q: Should I prioritize using cell supernatant or serum/plasma for immunosuppression
assessment?
+
A:
- Mechanism Research/In Vitro Models Priority Cell supernatant. The
signal source is clearer.
- Pharmacodynamics/Toxicology/Cohort Stratification Priority
Serum/PlasmaIt more closely reflects the systemic immune status, but greater attention
must be paid to matrix interference and individual differences.
- Local Tissue Environment (Tumor/Organ Inflammation) AvailableTissue
homogenate/lysis buffer Pay attention to normalization and background interference.
Q: If I can only measure 2 indicators, how can I choose to minimize misjudgment?
+
A: Look at your most pressing "decision-making issue":
- Determine if braking occurs: IL-10 + TGF-β1
- Determine whether the effect is insufficient: IL-2 + IFN-γ
- Determine if there is a bias toward change: IFN-γ + IL-4
- Determine if it is a chronic inhibitory environment: IL-6 + CCL2
